Welcome to the e-CCO Library!

DOP69: Glycans as an actor in the microbiome-immune response crosstalk.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Rodrigues, C.(1);Gaifem, J.(2);Pereira, M.(2);Lavelle, A.(3);Colombel, J.F.(4);Sokol, H.(5);Pinho, S.(6)*;
Created: Friday, 14 July 2023, 10:43 AM
DOP69: Long-term outcome of infantile and very early onset IBD: A multi-center study from the IBD Porto group of ESPGHAN
Year: 2022
Source: ECCO'22
Authors: Guz Mark, A.(1,2);Aloi, M.(3);Scarallo , L.(4);Bramuzzo, M.(5);Escher, J.C.(6);Alvisi, P.(7);Henderson, P.(8);Hojsak, I.(9);Lev-Tzion, R.(10);El-Matary, W.(11);Schwerd, T.(12);Weiss, B.(13);Sladek, M.(14);Strisciuglio, C.(15);Müller, K.(16);Olbjørn, C.(17);Tzivinikos, C.(18);Yerushalmy-Feler, A.(19);Christiaens, A.(20);Norsa, L.(21);Viola, I.(22);de Ridder, L.(6);Shouval, D.(23);Lega, S.(5);Lionetti, P.(24);Catassi, G.(25);Assa, A.(26);
Created: Friday, 11 February 2022, 3:52 PM
DOP69: Longitudinal gut microbiome dynamics in relation to disease flares in Inflammatory Bowel Disease, pilot data from the IBD-Tracker study
Year: 2024
Source: ECCO'24 Stockholm
Authors: Gacesa, Ranko
Created: Tuesday, 30 April 2024, 5:03 PM
DOP69: Ozanimod for induction treatment of Moderate-to-Severe Ulcerative Colitis: Results from a systematic literature review and network meta-analyses
Year: 2021
Source: ECCO'21 Virtual
Authors: Eaton, K.(1);Duperrouzel, C.(1);Bhandari, P.(1);Craigie, S.(1);Bonner, A.(1);Cameron, C.(2);Tencer, T.(3);Kumar, J.(3)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP69: The detection with targeted biopsy and characterisation of neoplastic lesions by magnifying chromoendoscopy and NBI in surveillance colonoscopy of patients with ulcerative colitis: a sub-analysis of the Navigator Study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

K. Watanabe*1,2, M. Esaki3, S. Oka4, F. Shimamoto5, M. Nishishita2, T. Fukuchi6, S. Fujii7, F. Hirai8, K. Kakimoto9, T. Inoue9, H. Kashida10, K. Takeuchi11, N. Ohmiya12, M. Saruta13, S. Saito14, Y. Saito15, S. Tanaka16, Y. Ajioka17, H. Tajiri13

Created: Friday, 22 February 2019, 9:41 AM
DOP69: Tofacitinib in Ulcerative Colitis: Early ‘real world’ experience from four United Kingdom tertiary centres
Year: 2020
Source: ECCO'20 Vienna
Authors: Desmond Chee
Created: Tuesday, 23 June 2020, 5:40 PM
DOP69: Tofacitinib in Ulcerative Colitis: Early ‘real world’ experience from four United Kingdom tertiary centres
Year: 2020
Source: ECCO'20 Vienna
Authors: Desmond Chee
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP70 High-dimensional analysis reveals a novel signature for IL-17 producing CD8 T cells in inflammatory bowel disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A.M. Globig1, P. Otto-Mora1, A. Hipp1, M. Heeg2, H. Schwacha1, V. Tomov3, R. Thimme1, P. Hasselblatt1, B. Bengsch1

Created: Thursday, 30 January 2020, 10:12 AM
DOP70: An integrated multi-omics biomarker predicting endoscopic response in ustekinumab treated patients with Crohn's disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

B. Verstockt*1,2, P. Sudahakar2,3,4, B. Creyns5, S. Verstockt6, J. Cremer5, W-J. Wollants2, S. Organe2, T. Korcsmaros3,4, M. Madgwick3, G. Van Assche1,2, C. Breynaert5, S. Vermeire1,2, M. Ferrante1,2

Created: Friday, 22 February 2019, 9:41 AM
DOP70: An integrated multi-omics biomarker predicting endoscopic response in ustekinumab treated patients with Crohn's disease
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Bram Verstockt
Created: Tuesday, 28 May 2019, 3:32 PM
Treat to target, Ustekinumab
Files: 1
DOP70: Anti-TNF withdrawal according to a risk-stratified protocol does not reduce the risk of relapse in patients with Inflammatory Bowel Disease in endoscopic remission: A prospective study
Year: 2022
Source: ECCO'22
Authors: Mahmoud, R.(1);Savelkoul, E.(2);Mares, W.(3);Goetgebuer, R.(4,5);Witteman, B.(3);de Koning, D.(6);Minderhoud, I.(7);van Tuyl, S.(8);van Boeckel, P.(9);Mahmmod, N.(9);Lutgens, M.(10);Horjus, C.(11);Römkens, T.(12);Akol-Simsek, D.(13);Jansen, J.(14);Hoentjen, F.(2,15);Jharap, B.(16);Oldenburg, B.(1);
Created: Friday, 11 February 2022, 3:52 PM
DOP70: Crohn's Disease Like Inflammation of The Pouch is a Distinct Type of Pouchitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Kayal, M.(1)*;Tankelevich, M.(2);Guo, Y.(3);Fischer, J.(4);Jimenez, D.(5);Canales-Herrerias, P.(2);Livanos, A.(2);Colombel, J.F.(1);Dubinsky, M.(6);Faith, J.(4);Ko, H.(3);Mehandru, S.(2);
Created: Friday, 14 July 2023, 10:43 AM
DOP70: Crohn’s Disease Like Inflammation of The Pouch is a Distinct Type of Pouchitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Maia Kayal
Created: Friday, 14 July 2023, 2:22 PM
DOP70: Exosomes derived from human umbilical cord mesenchymal stem cells to attenuate colitis through repairing intestinal mucosal barrier
Year: 2021
Source: ECCO'21 Virtual
Authors: Yang, S.(1);Liang, X.(1);Liu, A.(1);Zhang, X.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP70: High dimensional analysis reveals a novel signature for IL-17 producing CD8 T cells in Inflammatory Bowel Disease
Year: 2020
Source: ECCO'20 Vienna
Authors: Peter Hasselblatt
Created: Tuesday, 23 June 2020, 5:40 PM
DOP70: High dimensional analysis reveals a novel signature for IL-17 producing CD8 T cells in Inflammatory Bowel Disease
Year: 2020
Source: ECCO'20 Vienna
Authors: Peter Hasselblatt
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP71 Efficacy, safety, and tolerability of ustekinumab in paediatric patients with moderately to severely active Crohn’s disease: Results from, UniStar, a phase 1 study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J. Rosh1, D. Turner2, A. Griffiths3, D. Jacobstein4, O. Adedokun5, L. Padgett5, N. Terry5, C. O’Brien5, J. Hyams6

Created: Thursday, 30 January 2020, 10:12 AM
DOP71: Effects of ustekinumab induction therapy on endoscopic and histologic healing in the UNIFI phase 3 study in ulcerative colitis
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Katherine Li
Created: Tuesday, 28 May 2019, 3:32 PM
Histology, Ulcerative colitis, Mucosal healing, Ustekinumab, Mucosal healing, Mucosal healing
Files: 1